CORRUPTION AND FCPA VIOLATIONS IN THE MEDICAL DEVICE INDUSTRY

FCPA and worldwide anti-corruption enforcement activities in the life science industry are receiving increased attention with over $142 million in fines collected by DOJ and the SEC in 2012 alone. The current list of FCPA-related investigations for medical device companies is lengthy and penalties are substantial, with Johnson & Johnson having paid out the largest settlement resulting in approximately $70 million in fines. These activities demonstrate an ongoing trend that industry legal and regulatory professionals are well aware of – they have and will continue to be subject to heavily stringent FCPA oversight. The following presentation will provide attendees with further insight into the scope, nature and influence of corruption in the life science industry, while assessing the government and regulators’ capacity to manage and mitigate corruption within the US healthcare system.

• Update on current regulatory and enforcement activities
• Where are FCPA violations occurring and why
• Analysis of recent court cases and their impact – United States v. Esquenazi and United States v. Straub
• Framing compliance programs for best practices
• Recommendations for risk mitigation and compliance enhancement

Speaker:
Peter S. Spivack
Partner
Hogan Lovells US LLP